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Epstein–Barr virus, a human gammaherpesvirus, possesses a unique set of latent genes whose constitutive expression in
B cells leads to cell growth transformation. The initiation of this growth transforming infection depends on a viral promoter
in BamHI W (Wp) whose regulation is poorly understood. Using Wp reporter constructs in in vitro transfection assays, we
found that Wp was 11- to 190-fold more active in B cell than in non-B cell lines and that three regions of the promoter (termed
UAS1, UAS2, and UAS3) contributed to transcriptional activation. The upstream regions UAS3 (21168 to 2440) and UAS2
(2352 to 2264) both functioned in a cell lineage-independent manner and were together responsible for the bulk of Wp
activity in non-B cells; mutational analysis indicated the importance of a YY1 binding site in UAS2 in that context. By contrast,
UAS1 (2140 to 287) was B cell specific and was the key determinant of the promoter’s increased activity in B cell lines.
Mutational analysis of UAS1 sequences combined with in vitro bandshift assays revealed the presence of three binding sites
for cellular factors in this region. When mutations that abolished factor binding in bandshift assays were introduced into a
Wp reporter construct, the loss of any one of the three UAS1 binding sites was sufficient to reduce promoter activity by 10-
to 30-fold in B cells. From sequence analysis, two of these appear to be novel transcription factor binding sites, whereas the
third was identified as a cyclic AMP response element (CRE). Our data indicate that this CRE interacts with CREB and ATF1
proteins present in B cell nuclear extracts and that this interaction is important for Wp activity. © 1998 Academic Press
INTRODUCTION
Primary infection with Epstein–Barr virus (EBV), a hu-
man herpesvirus with B cell growth transforming ability,
is associated with a virus-driven expansion of latently
infected B lymphocytes. This process, which appears
crucial to the successful establishment of the virus car-
rier state, can be studied in vitro, where the experimental
infection of resting B lymphocytes leads to the outgrowth
of lymphoblastoid cell lines (LCLs) expressing nine virus-
encoded latent proteins; the nuclear antigens EBNAs 1,
2, 3A, 3B, 3C, and LP; and three latent membrane pro-
teins (LMP1, LMP2A, and LMP2B) (Kieff, 1996; Rickinson
and Kieff, 1996). Substantial progress has been made in
characterising the events occurring during transforma-
tion. After binding to the B cell surface receptor CR2
(CD21) (Nemerow et al., 1987; Tanner et al., 1987) and
subsequent internalisation of the virus, the first detect-
able viral transcripts initiate exclusively from a promoter
Wp located within each BamHI W repeat of the EBV
genome (Alfieri et al., 1991; Sample et al., 1986; Woi-
setschlaeger et al., 1990). Although these Wp-initiated
transcripts have the potential to encode all six EBNAs, at
this early time, viral antigen expression appears to be
restricted to EBNA2 and EBNA-LP (Alfieri et al., 1991).
EBNA2, acting either alone or in cooperation with EBNA-
LP, then serves to activate a number of viral and cellular
promoters that control the expression of genes critical
for subsequent stages of growth transformation; these
include the upstream BamHI C promoter (Cp), which acts
as an alternative promoter for EBNA transcription
(Rooney et al., 1992; Sung et al., 1991; Woisetschlaeger et
al., 1991), the viral promoters for all three LMPs (Abbot et
al., 1990; Fåhraeus et al., 1990; Nitsche et al., 1997; Wang
et al., 1990; Zimber-Strobl et al., 1991), and the promoters
of various cellular genes, including CD21, CD23, and
cyclin D2 (Cordier et al., 1990; Sinclair et al., 1994; Wang
et al., 1987). EBNA2-mediated activation of Cp is coinci-
dent with the broadening of antigen expression to all six
EBNAs and with the start of a gradual decline in the
levels of Wp transcripts (Woisetschlaeger et al., 1991),
consistent with the observation that Cp is the dominant
EBNA promoter in the majority of established LCLs (Al-
tiok et al., 1992). In common with other EBNA2-depen-
dent promoters, transactivation of Cp is mediated at
least in part through the interaction between EBNA2 and
a cellular factor, RBP-Jk (Grossman et al., 1994; Henkel et
al., 1994; Ling et al., 1993; Waltzer et al., 1994; Zimber-
Strobl et al., 1994), which recruits EBNA2 to its target
sequence. In addition to RBP-Jk, the Cp EBNA2 response
element contains a binding site for a second cellular
factor, CBF2 (Ling et al., 1993; Robertson et al., 1995), and
mutations in either of these two cognate sites can abol-
ish EBNA2-dependent Cp activation. Cp activity is also
positively regulated through the binding of EBNA1 to
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high-affinity sites in the upstream oriP sequence
(Puglielli et al., 1996; Sugden and Warren, 1989), the
latent origin of plasmid replication.
In contrast to Cp, the factors that govern Wp activity
remain poorly characterised. Previous studies have dem-
onstrated that Wp can operate in EBV-negative cells, but
there still is no clear consensus on the cell lineage
dependence of Wp activity or any detailed understanding
of Wp regulatory elements (Contreras-Brodin et al., 1996;
Nilsson et al., 1993; Ricksten et al., 1988; Rooney et al.,
1992). Jansson et al. (1992) described an upstream en-
hancer sequence, located between 2300 and 2135 rel-
ative to the RNA start site, which strongly stimulated Wp
expression in the EBV-negative Burkitt’s lymphoma (BL)
cell line DG75, but this element has not been analysed in
further detail. More recently, work with larger genomic
constructs has shown that the upstream oriP sequences
can positively regulate Wp expression in some B cell
lines, but this effect was detectable only in reporter
constructs in which the intervening Cp region was de-
leted (Puglielli et al., 1996). The present study focuses on
the cell lineage dependence of Wp activity, on the de-
tailed analysis of regulatory elements upstream of the
Wp transcription start site, and on the identification of
binding sites for a number of cellular transcription fac-
tors critical for Wp function.
FIG. 1. Deletion mapping of Wp regulatory sequences. (A) Schematic illustration of the region of the EBV genome containing the viral promoters
Cp and Wp active during latent infection in LCLs. Also shown are the splice patterns of Cp and Wp transcripts and the relative position of the latent
origin of replication, oriP. (Inset) Detailed map of Wp highlighting the position of restriction enzyme sites, relative to the Wp start site (11), used in
this work. (B) Effect of deleting 59 regulatory sequences on the activity of a series of Wp reporter constructs. The figure is a schematic representation
of a homologous series of Wp fragments, cloned into pGL2 Basic, each carrying the Wp RNA start site and different lengths of 59 regulatory
sequences; the name of each test promoter refers to the upstream limit of Wp sequence. Promoter activity was assayed by quantifying luciferase
expression in whole-cell lysates prepared from BJAB cells transiently transfected with derivatives of pGL2 Basic containing the indicated Wp
sequences. The reported luciferase values are from a single representative experiment and have been normalised for variations in transfection
efficiency by cotransfecting a second constitutive reporter plasmid, CMVb-Gal. All values are expressed relative to an arbitrary value of 1.0 set for
the level of luciferase activity in cells transfected with the empty control vector pGL2 Basic.
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RESULTS
Identification of regulatory sequences UAS1, UAS2,
and UAS3 within Wp
To characterise the proximal regulatory elements re-
quired for Wp expression, we first isolated a subfragment
of BamHIW extending from 21168 to 1173 relative to the
Wp RNA start site (11). The position of this subfragment
in its immediate context within the viral genome, down-
stream of oriP and Cp, is illustrated in Fig. 1A. These Wp
sequences were introduced into the luciferase reporter
pGL2 Basic, such that luciferase expression became
dependent on the cloned promoter fragment. The result-
ing plasmid, Wp1168/Basic, was then used to generate a
series of nested deletion mutants (illustrated in Fig. 1B)
carrying truncated Wp sequences down to the minimal
Wp87. The effect of these deletions on Wp activity was
first determined by introducing the reporter constructs
into BJAB, a reference EBV-negative B cell line, and then
measuring luciferase expression 24 h posttransfection;
in each case, the promoter activity was normalised for
differences in transfection efficiency by cotransfecting a
second plasmid, CMVb-Gal, which constitutively ex-
presses b-galactosidase.
Representative data from such an experiment are
shown in Fig. 1B, in which the activities of the various
reporter constructs are expressed relative to that of the
pGL2 Basic vector alone. It can be seen that removing
the sequences from 21168 to 2440 caused a significant
reduction in Wp activity in BJAB cells, indicating that this
distal sequence carries one or more positive regulatory
elements. We refer to this cis-acting sequence as up-
stream activating sequence 3 (UAS3). Further deletion of
the sequences from 2440 to 2352 had no discernible
effect, whereas removal of the sequences from 2352 to
2264 resulted in a second fall in activity, indicating that
this region of the promoter (UAS2) also contains regula-
tory sites important for Wp expression. Further deletions
to 2202, 2170, and 2140 had relatively small effects, but
the removal of sequences from 2140 to 2125 resulted in
another substantial drop in activity, indicating that a third
important element (UAS1) lies downstream of 2140. Al-
though the Wp sequences downstream from 2125 were
insufficient to activate luciferase expression when tested
in isolation, the data do not eliminate the possibility that
there may be regulatory elements downstream of 2125
that contribute to the activity of the Wp140 construct. In
summary, Fig. 1 shows that nucleotide sequences ex-
tending ;1 kb upstream of the Wp transcription start site
contribute to a .1000-fold activation of the promoter over
background levels and indicates that this activation is
largely dependent on three regions: UAS1 (defined as
2140 to 287), UAS2 (2352 to 2264), and UAS3 (21168
to 2440).
We next examined the extent to which Wp expression
is dependent on host cell type by determining the activity
of selected Wp reporter constructs relative to the empty
control vector pGL2 Basic in a range of different cell
lineages. Table 1 summarises the data from four inde-
pendent experiments on each of the cell lines tested. The
results show that all three cis-acting sequences (UAS1,
UAS2, and UAS3) contributed to Wp activation not just in
BJAB cells but also in the EBV-negative BL line DG75 and
in the EBV-positive BL lines Akata, Eli, and AG876. Based
on an average of the data from all five B cell lines, UAS1
contributed to a 12-fold activation in promoter activity
(compare Wp140 and Wp87), whereas UAS2 and UAS3
each contributed additional 4- to 5-fold increments in
activity (compare Wp440 and Wp264, and Wp1168 and
Wp440). It also is clear from Table 1 that the longest Wp
reporter construct (Wp1168) was 11- to 190-fold more
active in B cells than in the various non-B cell lines
tested; of the latter, Jurkat and CEM are of T cell origin,
K562 is a proerythroleukaemic line, and SVK is derived
from skin keratinocytes. Furthermore, from assays with
the truncated Wp constructs, promoter activity seen in
these non-B cells was found to be dependent on UAS3
and UAS2 but not on UAS1. Thus the UAS1-containing
TABLE 1
Effects of 59 Deletions on Wp Promoter Activity in Different Cell Lines
Test
promoter
UAS
elements
B cell Non-B cell
BJAB DG75 Akata-BL Eli-BL AG876 Jurkat CEM K562 SVK
Wp1168 3, 2 1 1 3640 (280) 1306 (210) 3240 (420) 1920 (180) 1320 (90) 113 (14) 19 (3.0) 40 (7) 19 (3.2)
Wp440 2 1 1 502 (98) 246 (36) 984 (110) 590 (85) 595 (68) 95 (7) 4.3 (1.1) 37 (4) 6.2 (0.8)
Wp352 2 1 1 650 (42) 284 (48) 414 (86) 313 (45) 205 (36) 104 (18) 9.3 (2.3) 37 (8) 7.8 (1.4)
Wp264 1 108 (8) 32 (3) 266 (43) 165 (27) 120 (16) 9 (2) 0.5 (0.2) 9 (1.4) 4.2 (0.4)
Wp140 1 34 (5) 30 (3) 230 (11) 156 (18) 20 (3) 9 (2) 0.6 (0.3) 7 (1.2) 5.6 (0.7)
Wp87 None 3 (0.2) 2 (0.1) 11 (1.0) 17 (2.0) 5 (0.8) 7 (1) 0.5 (0.2) 3 (0.5) 2.6 (0.3)
Note. Promoter activities were assayed by quantifying luciferase expression in whole-cell lysates prepared from cells transiently transfected with
the derivatives of pGL2 Basic. Each experimental value is the mean of four independent experiments and is shown with its standard deviation in
parentheses. All values have been corrected for differences in transfection efficiency by cotransfecting a second constitutive reporter plasmid CMV
b-Gal and are expressed relative to the level of luciferase activity in cells transfected with the empty control vector pGL2 Basic.
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constructs Wp140 and Wp264 had the same minimal
levels of activity in non-B cells as the UAS1-negative
construct Wp87; compared with these, larger constructs
containing UAS2 showed up to a 10-fold increase in
activity, and the additional presence of UAS3 mediated a
further 3- to 4-fold increase in some cell lines but not in
others. Overall, the data indicate that the promoter prox-
imal element UAS1 functions in a B cell-specific manner,
whereas both UAS2 and UAS3 can function in a wider
range of cell lineages.
UAS2 contains a YY1 binding site that contributes to
Wp activation
In an attempt to pinpoint sequences within UAS2 that
contributed to Wp activity, a preliminary mutational anal-
ysis was performed by introducing a series of random
double nucleotide substitutions, S1–S5, throughout the
UAS2 sequence, as detailed in Fig. 2A. The effects of
each of these UAS2 mutations was tested in the context
of the Wp 440 fragment by transfection into a B cell line,
Akata-BL, and into a non-B cell line, K562. The results,
illustrated in Fig. 2B, identified one mutation, S2, that
caused a significant reduction in Wp activity. We noted
that the S2 mutation altered the sequence 59-
CCATTTT-39 (position 2307 to 2301), which is an exact
match with the consensus binding site for a ubiquitously
expressed transcription factor YY1 (Park and Atchison,
1991; Shi et al., 1991). We therefore tested whether YY1
could interact with the relevant Wp sequence by means
of a bandshift assay. The results in Fig. 3A demonstrate
that incubation of a radiolabeled oligonucleotide probe
2308 to 2279 containing the putative YY1 site with a
nuclear extract prepared from DG75 cells results in one
abundant complex and several minor species (Fig. 3A,
FIG. 2. Mutational analysis of UAS2. (A) Schematic illustration of Wp 440 showing the location of UAS2, UAS1, and the Wp RNA start site. (Inset)
Nucleotide sequence from Wp from 2316 to 2260 showing the position of five nucleotide substitutions S1–S5 introduced into the Wp 440 sequence
by site-directed mutagenesis. (B) Effect of substitutions S1–S5 on Wp activity. Promoter activity was assayed by quantifying luciferase expression in
cells transiently transfected with derivatives of pGL2 Basic containing the indicated Wp 440 mutant sequences. The reported luciferase values are
the mean 6 standard deviation of three independent experiments and are expressed relative to control cells transfected with a derivative of pGL2
Basic containing the wild-type Wp 440 sequence.
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lane 2). The most abundant complex is specific to YY1
because the addition of excess unlabeled probe almost
completely abolished formation of this complex (lane 3);
in contrast, when a corresponding sequence containing
the S2 mutation or an unrelated Oct1 binding sequence
was added as competitor, there was no such effect
(lanes 4 and 5). Furthermore, this abundant YY1-specific
complex was not detectable when the S2-containing
sequence was used as a probe (lane 8), although the
weak nonspecific complexes were still present. The find-
ing that YY1 specifically interacts with this region of Wp
was confirmed in experiments using in vitro translated
(IVT) YY1 protein (Fig. 3A, lane 6); this yielded a similar
complex that comigrated with the most abundant com-
plex observed in DG75 extracts. The faster migrating
complexes seen in this track are probably due to degra-
dation products of IVT YY1 rather than to other proteins
in the wheat germ extract because neither these nor the
major complex was observed using a mock IVT reaction
(lane 7).
To further check the involvement of YY1 in Wp regula-
tion, we compared the activity of wild-type Wp 440 and
Wp 440 carrying the S2 mutation in an extended range of
cell lines. The results in Fig. 3B show that mutation of the
YY1 site reduced Wp expression by 30–40% in the three
different B cell lines, DG75, Ramos, and Akata-BL, but
had a consistently greater effect in the non-B cell lines
Jurkat, CEM, and K562, reducing activity by 65–80%. This
presumably reflects the fact that overall, Wp activity is
more dependent on UAS2 in non-B cells, where the UAS1
enhancer element is inactive.
Identification of regulatory sites within UAS1
We next focused our attention on the B cell-specific
enhancer UAS1 by introducing a series of mutations
throughout the 2140 to 287 region in the context of the
Wp440/Basic reporter plasmid. Details of the nucleotide
changes in these mutants, designated M1–M9, are given
in Fig. 4A. The effects of these changes on Wp activity in
a number of different cell lines were then determined by
measuring luciferase expression in transient transfection
assays. The results in Fig. 4B, summarising data ob-
tained from four independent experiments in each line,
show that the mutations designated M2, M3, M7, and M8
all reduced Wp expression in the B cell lines Ramos,
Akata-BL, and Eli-BL by 10- to 30-fold. In contrast, these
same four mutations reduced Wp activity in K562 cells by
only ;2-fold, which is consistent with the finding that
UAS1 does not contribute significantly to Wp activity in
FIG. 3. The cellular factor YY1 specifically interacts with sequences
in UAS2. (A) The figure shows protein–DNA complexes obtained by
incubating the probe carrying Wp sequences from 2308 to 2279 with
DG75 nuclear extracts or in vitro translated (IVT) YY1. (Inset) Sequence
of the wild-type probe and of its derivative containing nucleotide sub-
stitutions corresponding to the S2 mutation. Lane 1 indicates 2308 to
2279 probe alone; lane 2, probe with DG75 nuclear extract; lanes 3–5,
probe with DG75 nuclear extract and a 1000-fold excess of the indi-
cated competitor DNA fragment; lane 6, probe with IVT YY1; lane 7,
probe with mock IVT reaction; and lane 8, S2 probe incubated with
DG75 nuclear extract. The position of the YY1-specific complex is
shown by the filled arrowhead. (B) Effect of the S2 substitution in the
YY1 binding site on Wp reporter activity. Promoter activity was assayed
by quantifying luciferase expression in cells transiently transfected with
a derivative of pGL2 Basic containing the S2 mutant version of Wp 440.
In each case, the reported values are the mean 6 standard deviation
of two independent experiments and are expressed relative to control
cells transfected with a derivative of pGL2 Basic containing the wild-
type Wp440 sequence.
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this cell line; similar results were obtained with a second
non-B cell line (Jurkat) (data not shown).
Having identified four substitutions within UAS1 that
severely abrogated Wp function, we next examined
whether these same mutations affected the ability of
UAS1 sequences to interact with cellular factors. We
designed three overlapping oligonucleotide probes
(probe A, 2102 to 277; probe B, 2115 to 286; probe C,
2140 to 299; see Fig. 5) that completely spanned UAS1
and used each of these probes in turn to search for
interacting proteins in bandshift assays using DG75 nu-
clear extracts. The results obtained with probe A are
illustrated in Fig. 5A. This probe formed multiple com-
plexes (lane 2), all of which could be competed when
FIG. 4. Mutational analysis of UAS1. (A) Schematic illustration of Wp440 showing the location of UAS2, UAS1, and the Wp RNA start site. (Inset)
Nucleotide sequence of Wp from 2140 to 275 showing the position of nine double nucleotide substitutions (M1–M9) introduced into the Wp440
sequence by site-directed mutagenesis. (B) Effect of substitutions M1–M9 on Wp activity. Promoter activity was assayed by quantifying luciferase
expression in cells transiently transfected with derivatives of pGL2 Basic containing the indicated Wp440 mutant sequences. The reported luciferase
values are the mean 6 standard deviation of four independent experiments and are expressed relative to control cells transfected with a derivative
of pGL2 Basic containing the wild-type Wp440 sequence.
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challenged by the addition of unlabeled probe (lanes
3–5). These complexes were specific to probe A because
none of the species could be competed by the addition of
probe B (lane 7) or probe C (lane 8). To examine whether
the inactivating M8 mutation interfered with the binding
of cellular factors to this fragment, we resynthesised
probe A to contain the M8 mutation (probe A M8) and
used this new sequence as a competitor in the bandshift
assay. In contrast to the wild-type probe, this mutant
sequence did not compete for complex formation (lane
6), clearly indicating that the M8 mutation prevents the
binding of several factors to a single site, designated site
A, in UAS1.
Figure 5B shows the results of similar experiments
with probe B (i.e., Wp sequences 2115 to 286). This
probe formed a single specific complex (lane 2) that was
effectively competed by excess unlabeled probe B (lane
4) but not by either probe A (lane 3) or probe C (lane 5).
A competitor carrying the inactivating M7 mutation
(probe B M7) failed to compete this complex (lane 9),
indicating that this substitution prevents the binding of
the relevant cellular factor to UAS1. To further character-
ise the sequences required for binding of this factor, we
used various 59 and 39 truncated versions of probe B to
challenge complex formation. Of the 59 truncations, the
sequence 2110 to 286 (lane 6) was just as effective a
competitor as probe B itself (lane 4), whereas the shorter
sequence 2105 to 286 (lane 7) failed to compete. A 39
truncation, the sequence 2115 to 290 (lane 8), also
competed as effectively as probe B. Taken overall, these
data show that sequences required for binding of the
cellular factor must lie between 2110 and 290, desig-
nated site B.
Figure 5C shows the results obtained with probe C,
carrying the Wp sequences 2140 to 299. In this case,
three complexes were formed (lane 2), all of which were
judged to be specific from the results of competition
experiments using excess cold probe (lane 3). To deter-
mine whether these three complexes were due to dis-
tinct factors binding to separate sites in probe C, we
again used a series of truncated sequences as compet-
itors to delineate the 59 and 39 limits of the binding site.
FIG. 5. Cellular factors bind to three distinct sites in UAS1. (A) Protein–DNA complexes obtained by incubating probe A (2102 to 287) with DG75
nuclear extracts. Lane 1 indicates probe A alone; lane 2, probe with DG75 nuclear extract; lanes 3–5, probe with DG75 nuclear extract and a 1000-,
100-, and 10-fold excess unlabeled probe A, respectively; and lanes 6–8, probe with DG75 nuclear extract and a 1000-fold excess of the indicated
competitor DNA fragment. The sequence of probe A and the mutant derivative carrying the M8 substitution are shown below the figure. (B)
Protein–DNA complexes obtained by incubating probe B (2115 to 286) with DG75 nuclear extracts. Lane 1 indicates probe B alone; lane 2, probe
with DG75 nuclear extract; and lanes 3–9, probe with DG75 nuclear extract and a 1000-fold excess of the indicated competitor DNA fragment. Shown
below the figure are the sequences of probe B and the mutant derivative carrying the M7 substitution. Truncated fragments carrying the Wp
sequences 2110/286, 2105/286, and 2115/290 (not shown) were also used as competitors where indicated. (C) Protein–DNA complexes obtained
by incubating probe C (2140 to 299) with DG75 nuclear extracts. Lane 1 indicates probe C alone; lane 2, probe with DG75 nuclear extract; and lanes
3–10, probe with DG75 nuclear extract and a 1000-fold excess of the indicated competitor DNA fragment. Shown below the figure is the sequence
of probe C and two derivatives carrying the substitutions M2 and M3. Truncated fragments carrying the sequences 2125/299, 2120/299,
2140/2111, 2140/2116, and 2125/2111 (not shown) were also used as competitors where indicated.
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The results of these mapping experiments suggested
that all three complexes were due to the binding of
multiple factors to the same sequence, designated site
C, extending from 2125 (compare lanes 4 and 5) to 2111
(compare lanes 6 and 7). This was further confirmed by
the ability of the 2125 to 2111 oligonucleotide to com-
pete out the binding of all three complexes to probe C
(lane 8). Importantly, when probe C was resynthesised to
contain either of the inactivating mutations M2 or M3,
competitor function was lost (lanes 9 and 10), indicating
that both of these mutations disrupt the binding of all
three factors to this site.
Site A of UAS1 binds members of the CREB/ATF
family of transcription factors
An analysis of UAS1 sites B and C using the tran-
scription factor database (Wingender et al., 1996)
failed to reveal the presence of any previously defined
regulatory motifs, implying that these two elements
represent binding sites for as-yet-unrecognised tran-
scription factors. However, inspection of site A re-
vealed the presence of a cAMP response element
(CRE), 59-TTACGTAA-39, which differs from the consen-
sus CRE, 59-TGACGTCA-39, at just two positions. CRE
sequences bind members of the CREB/ATF family of
transcription factors that regulate gene expression in
response to changes in cAMP-dependent signaling
pathways (Lalli and Sassone-Corsi, 1994; Meyer and
Habener, 1993). To further investigate the role of
CREB/ATF factors in Wp activation, we asked whether
CREB and ATF1 proteins could interact with site A in
bandshift assays. The results shown in Fig. 6 indicate
that both IVT CREB (lane 3) and IVT ATF1 (lane 4) bind
probe A and that these specific complexes comigrate
with the complexes previously observed using DG75
nuclear extracts (lane 2); furthermore, the complexes
formed by IVT CREB and IVT ATF1 could be specifi-
cally competed by excess probe A but not by probe A
containing the M8 mutation (data not shown). As an
independent means of demonstrating CREB/ATF bind-
ing to site A, we used a monoclonal antibody (mAb)
that specifically recognises the leucine zipper/DNA
binding domain of CREB/ATF. The addition of this mAb
to the binding reaction containing DG75 nuclear ex-
tract resulted in multiple supershifted complexes (lane
5) consistent with the binding of CREB/ATF proteins to
this sequence; similar supershifted complexes were
observed when this same mAb was added to com-
plexes containing IVT CREB and IVT ATF1 (lanes 6 and
7). Together with the data showing that mutation of this
CRE element greatly reduces Wp activity (Fig. 4), these
results strongly imply a role for CREB/ATF factors in
the regulation of Wp expression in B cells.
DISCUSSION
There are important questions to be addressed re-
garding Wp function: What are the critical sequences that
regulate promoter activity? What are the cellular factors
mediating regulation at these sites? To what extent is Wp
activity cell lineage restricted? On the first two points,
there is relatively little published information and no
detailed analysis. On the third point, there is conflicting
evidence; thus early reports indicated that Wp contained
a B cell-specific enhancer (Jansson et al., 1992; Ricksten
et al., 1988), whereas a more recent report suggested
that Wp reporters were active in both B and non-B cell
lines (Contreras-Brodin et al., 1996). The extreme tropism
that EBV displays for B lymphocytes in vitro means that it
has been difficult to study Wp use by the viral genome
during the initiation of a virus infection in other cell types.
One exception, however, is the work with human epithe-
lial cell lines in which experimental infection can be
achieved in transfectants expressing the EBV receptor
CR2 (Knox et al., 1996). Under these circumstances, most
viral transcription appeared to initiate from Qp, an alter-
native latent cycle promoter that selectively expresses
EBNA1 mRNA and is active in EBV-associated malignan-
cies such as BL and nasopharyngeal carcinoma (Non-
kwelo et al., 1996; Sample et al., 1991; Schaefer et al.,
FIG. 6. Site A binds members of the CREB/ATF family. The figure
shows protein–DNA complexes obtained by incubating probe A with
DG75 nuclear extracts or in vitro translated CREB and ATF1 proteins.
Lane 1 indicates probe A alone; lane 2, probe with DG75 nuclear
extract; lane 3, probe A with IVT CREB; lane 4, probe A with IVT ATF1;
and lanes 5–7, same as lanes 3–5 but incubated in the presence of an
mAb that specifically recognises the bZIP domain of CREB/ATF/CREM
proteins. The position of specific complexes due to the binding of CREB
and ATF1 are shown by the open arrowheads, and the supershifted
complexes are marked by the filled arrowheads.
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1991, 1995; Smith et al., 1992). Interestingly, however, low
levels of (apparently abortive) Wp transcription were also
detectable in these acutely infected epithelial cells, sug-
gesting that Wp may not be entirely under the control of
B cell-specific factors.
The present work with a series of Wp reporter con-
structs shows that overall levels of Wp activity are 11- to
190-fold higher in B than in non-B cell lines. Three up-
stream regions, UAS3 (21168 to 2440), UAS2 (2352 to
2264), and, particularly, UAS1 (2140 to 287), all contrib-
ute to the high levels of Wp activity seen in a B cell
environment. In contrast, only two of these regions, UAS3
and UAS2, appear to operate in non-B cells, where they
account for most of the observed Wp activity. Interest-
ingly, the relative contribution of these two sequences
varied from one non-B cell line to another; thus in Jurkat
and K562, UAS2 was responsible for the majority of Wp
expression, whereas in CEM and SVK, sequences within
UAS3 also had weak positive effects. The most important
conclusion from these initial assays (Fig. 1, Table 1) is
that UAS1 functions as a B cell-specific enhancer of Wp
transcription. It should be noted that both UAS1 and
UAS2 overlap the region of Wp previously described as
an enhancer of Wp expression (Jansson et al., 1992;
Ricksten et al., 1988). The results presented here there-
fore extend these previous findings by showing that
there are in fact two sequences in this region of the
promoter that can contribute to Wp activation, UAS1 and
UAS2, and that a third previously undefined upstream
element, UAS3, also exists.
When a number of random mutations within UAS2
were tested in the context of the Wp 440 reporter, one
mutant, S2, was identified as having significantly re-
duced activity (Fig. 2). This fell within a sequence, 59-
CCATTTT-39, matching the consensus binding site for the
known transcription factor YY1. Bandshift assays con-
firmed that IVT YY1 can specifically interact with the
2308 to 2279 subfragment of UAS2, that a similar com-
plex is formed using B cell nuclear extracts, and that this
binding is abrogated by the S2 mutation (Fig. 3). We
conclude that YY1 contributes to the activity of UAS2;
furthermore, the observation that YY1 is constitutively
expressed in many cell types (Shrivastava and Calame,
1994) is in accord with our present finding that UAS2
functions in a cell lineage-independent manner. We note,
however, that mutation of the YY1 site does not com-
pletely abrogate UAS2 activity, even in non-B cell lines in
which its effects are most marked. Hence, other, as yet
unrecognised, factors may also be important in that con-
text.
The key sequences that determine the preferential
activity of Wp in B cells lie within the UAS1 region and
were identified by mutational analysis (Figs. 4 and 5).
Two of the inactivating mutations (M2 and M3) were
adjacent to each another and lay within a single binding
site, site C (2125 to 2111), identified in bandshift assays.
The three complexes formed at this site were equally
affected in competition assays, and all failed to bind to
sequences carrying the M2 or M3 mutation, suggesting
that all three factors interact with precisely the same
sequence. Another inactivating mutation (M7) identified
a second site within UAS1, site B (2110 to 290), which
interacted with a single factor in bandshift assays. The
fact that neither site B nor C contains sequences resem-
bling known transcription factor binding sites (Wingen-
der et al., 1996) implies that they may be targets for novel
cellular regulators. By contrast, site A (2102 to 277),
identified through the effects of another mutation (M8),
contains a sequence 59-TTACGTAA-39 that is closely re-
lated to the consensus CREB/ATF binding site. The de-
tection in bandshift assays of multiple protein–DNA com-
plexes at this site (Fig. 5A) is not unexpected because
there are many members of this family of bZIP transac-
tivators (Meyer and Habener, 1993). Using an mAb spe-
cific for the bZIP DNA binding domain of CREB/ATF1/
CREM, we confirmed that the complexes formed at site A
in the presence of DG75 cell nuclear extracts consist of
CREB and ATF1 homodimers, a finding supported by the
results of reconstruction experiments demonstrating that
IVT CREB and IVT ATF1 produced similar complexes in
bandshift assays (Fig. 6). The fact that the M8 mutation,
which disrupts CREB/ATF binding, dramatically reduces
the activity of a Wp reporter in B cell lines (Figs. 4 and 5)
strongly implies that this CRE plays an important role in
B cell-specific Wp activation.
Whilst this work was being completed, a report was
published (Sugano et al., 1997) that identified another
potential regulatory site within Wp. The authors reported
that a sequence downstream of UAS1 and close to the
Wp transcription start site (251 to 242, 59-GGGGGAC-
CAC-39) was capable of binding the transcription factor
NF-kB (consensus site 59-GGGACTTTCC-39). We have
been unable to repeat this observation using various
probes spanning the Wp sequence in this region, even
using B cell extracts that contained abundant NF-kB as
detected by binding to the known NF-kB site in the HIV
LTR (unpublished data). Sugano et al. (1997) also re-
ported that transient overexpression of the p50 subunit,
or coexpression of the p50 and p65 subunits of NF-kB,
enhanced the activity of a cotransfected Wp reporter in
the human embryonic kidney cell line 293. For this rea-
son, we specifically mutated the putative NF-kB site
[introducing the same mutations reported by Sugano et
al. (1997) to block NF-kB binding] and tested these in the
context of our standard Wp440 reporter; there was no
detectable effect on Wp activity in the B cell lines BJAB,
DG75, and Akata-BL. Further work will be required to
reconcile these apparently contradictory findings.
From the present study, we propose that a number of
binding sites for cell regulatory proteins influence Wp
activity in B cells, but among the most important are
three adjacent sites lying within the UAS1 region 87–140
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nucleotides upstream of the transcription start site. One
of these sites binds members of the CREB/ATF family,
whereas the identity of the factors binding at the other
two sites remains to be determined. Interestingly, we
found that although UAS1 functions in a B cell-specific
manner and its activity is strongly dependent on the
integrity of all three sites, the cellular factors binding to
these sites in bandshift assays are not themselves re-
stricted to B cells. Thus similar patterns of bandshifts to
those illustrated in Fig. 5 were also produced in the
presence of extracts from non-B cell lines such as K562
and Jurkat (unpublished data). This indicates that the
mere presence of these factors is not sufficient for UAS1
activity and suggests that additional components or ac-
tivation steps are required that are only functional in B
cells. In this context, it is interesting to note that a novel
pathway of CREB activation has recently been reported
in a B cell system, where in response to surface immu-
noglobulin ligation, CREB is phosphorylated not by the
usual protein kinase A pathway but rather by protein
kinase C (Xie et al., 1996).
Finally, we draw attention to the fact that the present
analysis has focused on regulatory sequences within 1
kb of the Wp transcription start site. Although we believe
that these sequences will play a role in Wp activation in
EBV-infected B cells, clearly, promoter activity may be
further modulated by long-range effects in the broader
context of the viral genome, and these may become
particularly important as the infection proceeds. Thus
others have found that placing an oriP sequence up-
stream of a Wp reporter can enhance promoter activity in
certain cell lines, presumably through the recruitment of
EBNA1 (Puglielli et al., 1996). However, in larger genomic
constructs carrying oriP-Cp-Wp in their natural orienta-
tion, Wp activity is suppressed by the presence of a
functional Cp, perhaps reflecting transcriptional interfer-
ence from the upstream promoter (Puglielli et al., 1997;
Woisetschlager et al., 1990). Interestingly, in such
genomic constructs, Cp transcription was itself en-
hanced by a region within Wp (Puglielli et al., 1997; Walls
and Perricaudet, 1991) that includes the UAS1 and UAS2
elements identified in the present work. It remains to be
seen whether the particular binding sites shown here to
influence Wp activity are also responsible for effects on
Cp. Clearly, the complex interplay between these two
adjacent promoters and their regulatory elements re-
mains important for a proper understanding of the early
events of B cell infection.
MATERIALS AND METHODS
Maintenance of cell lines
Transient assays were performed using a number of B
and non-B cell lines. BJAB is an EBV-negative B lym-
phoma cell line, Ramos and DG75 are EBV-negative BL
cell lines, Akata-BL and Eli-BL are EBV-positive BL cell
lines showing a form of infection in which EBNA1 is the
only viral protein detected, and AG876 is a BL cell line
that has switched to a form of infection in which all nine
viral latent proteins are expressed. Of the non-B cell
lines, Jurkat and CEM are of leukaemic T cell origin, K562
is a proerythroleukaemic line, and SVK was generated by
SV40-induced transformation of human keratinocytes. All
cell lines except SVK were maintained as suspension
cultures in growth medium containing RPMI 1640 sup-
plemented with 2 mM glutamine, gentamicin (100 mg/l),
and 10% (v/v) selected foetal calf serum (Life Technolo-
gies). SVK cells were grown in Joclics medium supple-
mented with 8% foetal calf serum, 2 mM glutamine, and
0.4 mg/ml hydrocortisone.
Plasmid constructions
Throughout this work, we used standard recombinant
DNA methods as described by Sambrook et al. (1989),
and all plasmid manipulations were performed using the
Escherichia coli strain XL1 Blue (Stratagene). The lucif-
erase reporter construct pGL2 Basic was obtained from
Promega. pGL2 Basic is a promoterless luciferase ex-
pression vector used to monitor promoter activity of test
DNA fragments. CMVb-Gal consists of the E. coli b-ga-
lactosidase gene driven by the human cytomegalovirus
(CMV) immediate-early promoter. The full-length cDNAs
for rat CREB and human ATF1 and for human YY1 were
kindly provided by Dr. H. Hurst (ICRF Oncology Unit,
Hammersmith Hospital, U.K.) and by Dr. J. Sinclair (De-
partment of Medicine, University of Cambridge, Adden-
brookes Hospital, U.K.), respectively. For the purpose of
in vitro transcription–translation experiments, all cDNAs
were cloned under the control of the bacteriophage T7
promoter in the expression vector pcDNA3 (InVitrogen).
Synthetic oligonucleotides for site-directed mutagenesis
and bandshift probes were purchased from Alta Bio-
science, The University of Birmingham.
The starting point for this work was the 1343-bp Bam-
HI–AvrII subfragment of the EBV BamHI W repeat, which
carries the nucleotide sequences of the BamHI W pro-
moter Wp from 21168 to 1175 (Baer et al., 1984; Sample
et al., 1986); the nucleotide sequences are numbered
with respect to the Wp RNA start site (see Fig. 1). This
fragment, termed Wp1168, was inserted between the
BglII and NheI sites of the luciferase reporter vector
pGL2 Basic such that luciferase expression became de-
pendent on the cloned promoter fragment. In the result-
ing plasmid Wp1168/Basic, Wp sequences are flanked
upstream and downstream by unique KpnI and HindIII
sites, respectively. The Wp440 and Wp352 derivatives of
pGL2 Basic were constructed by ligating the BglII–Hin-
dIII and SacI–HindIII subfragments of Wp1168, respec-
tively, into pGL2 Basic. The Wp264 derivative was con-
structed by cloning the AvrII–AvrII subfragment into the
NheI site of pGL2 Basic. The shortest Wp construct,
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Wp87, was generated by deleting the sequences be-
tween the SacI and SnaBI sites of Wp264/Basic and
recircularising the vector. Five additional derivatives
(Wp232, Wp202, Wp170, Wp140, and Wp105) containing
nested deletions in the 59 Wp regulatory sequences were
constructed by PCR amplification of Wp sequences. In
each case, the appropriate 59 primer (containing addi-
tional flanking sequences carrying a SacI site) and a
common 39 primer, which annealed just downstream of
the HindIII site in pGL2 Basic, were used to amplify a
specific subfragment of Wp. The amplified DNA products
were digested with SacI and HindIII, and the resultant
Wp-containing fragments ligated into pGL2 Basic. All Wp
derivatives carry the same BamHI W and pGL2 Basic
DNA sequences downstream of the Wp RNA start site.
Derivatives of Wp carrying specific mutations in either
UAS1 or UAS2 were constructed by site-directed mu-
tagenesis of the Wp440 fragment, cloned in M13 mp18,
using a synthetic mutagenic oligonucleotide and the
Sculptor in vitro mutagenesis system (Amersham). After
verification of the presence of the desired mutation by
dideoxy sequencing (Pharmacia T7 sequencing kit), mu-
tant Wp440 sequences were transferred into pGL2 Basic
as KpnI–HindIII fragments.
Transient transfections
For electroporation of suspension cell cultures, 107
cells in 400 ml of HEPES-buffered DME containing 10%
FCS, 8 mg of luciferase reporter, and 2 mg of CMVb-Gal
were placed in a 1-ml electroporation cuvette with an
electrode spacing of 4 mm. The cells were pulsed at 960
mF and at a predetermined optimum voltage for each cell
line (310 V for CEM and 270 V for all other cell lines)
using a BioRad Gene Pulser and then transferred to 5 ml
of RPMI 1640 growth medium in 3.5-cm-diameter cell
culture dishes. Cell suspensions were cultured for 16–24
h at 37°C before being harvested and used to prepare
whole-cell lysates for reporter gene assays.
Adherent SVK cells were transfected using a modifi-
cation of the DEAE-dextran method. Briefly, 1 3 106 cells
were plated onto 25-cm2 flasks, and on the next day, the
monolayers were washed with PBS to remove residual
serum. Then, 2.5 ml of transfection mixture containing
200 mg/ml DEAE dextran, 200 mM chloroquine, 8 mg of
luciferase reporter, and 2 mg of CMVb-Gal in DME was
added to each flask, and the cells were incubated for 2 h
at 37°C. The transfection mixture then was removed, and
the cells were washed with PBS and treated with 10%
DMSO in PBS for 2 min, followed by two washes with
PBS and the addition of growth medium.
Reporter gene assays
The activity of different Wp constructs was assayed by
quantifying luciferase expression in whole-cell lysates
prepared from cells transiently transfected with deriva-
tives of pGL2 Basic. At 16–24 h posttransfection, cells
were washed in PBS and then lysed in 200 ml of lysis
buffer (100 mM HEPES, pH 8, 2 mM magnesium chloride,
5 mM dithiothreitol, 2% Triton X-100). Luciferase activity
was determined by the addition of 100 ml of luciferase
assay reagent (20 mM glycylglycine, pH 7.9, 5 mM mag-
nesium chloride, 0.1 mM EDTA, 33 mM dithiothreitol, 270
mM coenzyme A, 470 mM beetle luciferin, and 530 mM
ATP) to 50 ml of lysate and then measuring light emission
for 10 s in a Berthold LB9501 luminometer. The luciferase
activity in each sample was then normalised for varia-
tions in transfection efficiency by measuring the level of
b-galactosidase expression from a cotransfected CMVb-
Gal plasmid. After incubation of the residual cell lysate at
50°C for 1 h, a 20-ml aliquot was mixed with 200 ml of
substrate (AMPGD, Tropix) and left for 1 additional h at
room temperature. b-Galactosidase activity was deter-
mined by the addition of 300 ml of Emerald reagent
(Tropix) and then measurement of light emission for 5 s
in a Berthold LB9501 luminometer.
Nuclear extract preparation
Crude nuclear extracts for use in bandshift experi-
ments were prepared using a simplified method of Dig-
nam et al. (1983). Briefly, 10–20 3 106 cells were pelleted,
washed once in PBS, and then lysed in 100 ml of buffer
A (10 mM HEPES, pH 7.9, 1.5 mM magnesium chloride, 10
mM potassium chloride, 0.5 mM dithiothreitol, 0.2% Non-
idet P-40) and freshly supplemented with the protease
inhibitors (100 mg/ml) phenylmethylsulfonyl fluoride, leu-
peptin, benzamidine, and aprotinin. The nuclei were col-
lected by centrifugation at 13,000 rpm for 1 min, resus-
pended in 100 ml of buffer C (5 mM HEPES, pH 7.9, 420
mM NaCl, 1.5 mM magnesium chloride, 26% glycerol, 0.5
mM dithiothreitol, 0.2 mM EDTA, and protease inhibitors
as before) and incubated for an additional 30 min on ice.
The samples were centrifuged again at 13,000 rpm for 1
min to pellet cell debris, and the cleared nuclear extracts
were stored in small aliquots at 270°C until needed.
Bandshift assays
The sequences of double-stranded oligonucleotide
probes for use in bandshift assays are shown in the
relevant figures. Probes were end-labeled using polynu-
cleotide kinase (Boehringer-Mannheim) and g-32P-ATP
(3000 Ci/mmol; Amersham). In vitro binding reactions
typically contained 2 ml of nuclear extract (5–10 mg of
protein), 2 mg of poly(dI/dC) (Pharmacia), and 1 fmol of
radioactively labeled DNA fragment (added last). Where
indicated, competitor DNA fragments (1 pmol) were
added to the binding reaction before the addition of the
labeled probe. This mixture was incubated on ice for 30
min before being loaded onto a 5% polyacrylamide gel
containing 0.53 TBE buffer and electrophoresed for 2–4
hr at 30 mA. Gels were dried and exposed to x-ray film
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overnight at 220°C. In experiments involving the binding
of CREB/ATF factors to probe A, poly(dI/dC) was re-
placed with herring sperm DNA (Sigma) as the nonspe-
cific competitor. Where indicated, 2–5 ml of in vitro trans-
lated YY1, CREB, and ATF1 proteins, prepared using an in
vitro wheat germ transcription/translation system (Pro-
mega TNT), were included in the binding reactions in
place of nuclear extracts. For supershift experiments, the
binding reactions were incubated with 2 ml of mAb
(25C10G, Santa Cruz Biotechnology), which specifically
recognises the conserved bZIP domain of CREB/ATF/
CREM proteins, for 30 min at room temperature before
the addition of the labeled fragment.
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